Kracer SB, Alduncin LN

Language: Spanish
References: 33
Page: 355-367
PDF size: 89.86 Kb.

ABSTRACT

Aspirin is the most prescribed anti-inflammatory and analgesic-antipyretic agent, and constitutes the standard compound in the comparison and assessment of other products. Its analgesic, anti-inflammatory, antipyretic and antiplatelet activity has been described and nowadays an antioxidant effect is proposed. Its anti-inflammatory activity has been related to a possible reduced risk to develop certain cancers and neuro-degenerative diseases. A clear benefit has also been demonstrated in the prevention of cardiovascular diseases, in such cases, it is important to assess individually the risk-benefit ratio. However, aspirin has also important adverse effects, which may limit its prescription; thus new compounds have been developed, which are less toxic and have more selective activity. This article reviews the therapeutic applications and the adverse effects of aspirin.

REFERENCES

1. Goodman Gilman A, Ruddon R, Molinoff P, et al. Las bases farmacológicas de la terapéutica. 9ª ed. México: McGraw-Hill Interamericana, 1996;pp:661-76.

2. Awtry E, Loscalzo JA. Aspirin. Circulation 2000;101(10):1206-18.

3. Vane J. Aspirin and other anti-inflammatory drugs. Thorax 2000;55(Suppl 2):S3-S9.

4. Wolfe M, Lichtenstein D, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflamatory drugs. N Engl J Med 1999;340:1888-98.

5. Suresh B, Sundeep S. Aspirin and asthma. Chest 2000;118(5):1470-6.

6. Jordan S, White J. Nonsteroidal antiinflamatory drugs: clinical issues. Nurs Stand 2001;15(23):45-54.

7. Weisman S, Graham D. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002;162:2197-202.

8. Lauer M. Aspirin for primary prevention of coronary events. N Engl J Med 2002;346(19):1468-74.

9. Eidelman R, Hebert P, Weisman S, et al. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003;163:2006-10.

10. Bhatt D, Chew D, Hirsch A, et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001;103:363-8.

11. Lefkovits J, Plow E, Topol E. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332(23):1553-9.

12. Boltri J, Akerson M, Vogel R. Aspirin prophylaxis in patients at low risk for cardiovascular disease: a systemic review of all-cause mortality. J Fam Pract 2002;51(8):700-4.

13. Collins R, Peto R, Baigent C, et al. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997;336(12):847-60.

14. Hart R, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131(7):492-501.

15. Golzari H, Cebul R, Bahler R. Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Ann Intern Med 1996;125(4):311-23.

16. Taylor F, Cohen H, Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ 2001;322:321-6.

17. He J, Whelton P, Vu B, et al. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA 1998;280(22):1930-5.

18. Derry S, Loke YK. Risk of gastrointestinal hemorrhage with long term use of aspirin: meta-analysis. BMJ 2000;321:1883-7.

19. Shris P, Cannon C, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998;129(5):394-405.

20. Gorelick P, Born G, D’Agostino R, et al. Therapeutic benefit: aspirin revisited in light of the introduction of clopidogrel. Stroke 1999;30(8):1716-21.

21. Rauch U, Osende J, Fuster V, et al. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med 2001;134:224-38.

22. Plaisance K, Mackowiak P. Antipyretic therapy: physiologic rationale, diagnostic implications, and clinical consequences. Arch Intern Med 2000;160(4):449-56.

23. Kowalski M. Rhinosinusitis and nasal polyposis in aspirin sensitive and aspirin tolerant patients: are they different? Thorax 2000;55(Suppl 2):S84-S86.

24. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004;328:434.

25. Chow E, Cherry J, Harrison R, et al. Reassessing Reye syndrome. Arch Pediatr Adolesc Med 2003;157:1241-2.

26. Glasgow JFT, Middleton B. Reye syndrome: insights on causation and prognosis. Arch Dis Child 2001;85:351-3.

27. Duley L, Henderson-Smart D, Knight M, et al. Antiplatelet drugs for preventions of pre-eclampsia and its consequences: systematic review. BMJ 2001;322(7282):329-33.

28. Etminan M, Gill S, Samii A. Effect of nonsteroidal antiinflamatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studies. BMJ 2003;327:327-30.

29. Schiess M. Nonsteroidal antiinflamatory drugs protect against Parkinson neurodegeneration: can an NSAID a day keep Parkinson disease away? Arch Neurol 2003;60:1043-4.

30. Paterson JR, Lawrence JR. Salicylic acid: a link between aspirin, diet and the prevention of colorectal cancer. QJM 2001;94(8):445-8.

31. Chan EL, Giovannucci ES, Schernhammer GA, et al. A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med 2004;140:157-66.

32. Ladabaum U, Chopra CL, Huang G, et al. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer: a cost effectiveness analysis. Ann Intern Med 2001;136:769-81.

33. Basler JW, Piazza GA. Nonsteroidal antiinflammatory drugs and cyclooxygenase-2 selective inhibitors of prostate cancer chemoprevention. J Urol 2004;171:S59-S63.